Zentalis Pharmaceuticals Secures FDA Alignment on Azenosertib Dose After Type D Meeting for Accelerated Approval

A Type D meeting with the FDA has cleared a critical path variable for Zentalis Pharmaceuticals, confirming no agency objection to the 400mg QD 5:2 monotherapy dose of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, a signal that carries direct weight for regulatory affairs teams tracking biomarker-driven accelerated approval strategies in oncology.

The FDA acknowledged that the DENALI Part 2 study population, encompassing cohorts 2a, 2b, and the currently enrolling 2c, has the potential to support an accelerated approval pathway, contingent on data strength and the competitive landscape of approved agents at the time of regulatory action. Enrollment in Parts 2a and 2b is complete; Part 2c expansion was added to broaden the study population and enrich for patients previously treated with a taxane-containing regimen, aligning the cohort with the evolving approved-agent landscape, a design adjustment that reflects the kind of mid-study regulatory responsiveness now expected under 21 CFR Part 312 accelerated approval frameworks.

For regulatory affairs leads, the Type D meeting outcome illustrates a deliberate de-risking maneuver: dose selection anchored to a pre-specified interim analysis from Part 2a, then validated through direct agency dialogue before topline data generation. The integrated dataset across all three DENALI cohorts is designed to carry the NDA/BLA submission, with a topline readout targeted for 1H 2027 to allow adequate data maturation post full enrollment.

The confirmatory ASPENOVA Phase 3 trial, which dosed its first patient in May 2026, runs in parallel to satisfy full approval requirements, a dual-track structure that regulatory operations teams will recognize as standard practice following the Accelerated Approval Program reforms under the Omnibus legislation. Zentalis reported $174.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, extending runway into late 2027 and covering execution through both key readouts.

The DENALI topline readout in 1H 2027 will be the first measurable test of whether the FDA-aligned study population and dose selection translate into a submission-ready efficacy signal for this biomarker-selected indication.

Source: Zentalis Pharmaceuticals via GlobeNewswire, August 6, 2026.